Last updated: April 24, 2026
What is Corvert in scope?
Corvert is a branded pharmaceutical product whose active ingredient is ibutilide (marketed for arrhythmia indications). Supplier mapping for “Corvert” itself is constrained by the fact that branded drug trade names sit on top of multiple upstream inputs (API, sterile fill-finish, device/packaging, and specialized reagents). The supplier set below targets the typical upstream supply chain segments that determine continuity of manufacturing for sterile injectable cardiovascular drugs.
Who supplies the ibutilide API supply chain?
Ibutilide API supply typically concentrates in a small set of global fine-chemical and API manufacturers able to execute high-control synthesis, purification, and compliance documentation. For Corvert-like sterile injectable launches, sourcing is usually structured as:
- API manufacturer(s) supplying ibutilide fumarate or ibutilide hemifumarate intermediates and final API
- API secondary processors (salt form control, crystallization, polymorph control) where required
- Quality and regulatory documentation providers (QMS document control, CoA/CEP support, GMP batch release documentation)
Direct named supplier identification requires brand-to-plant mapping (manufacturer of record and API sites tied to the product’s regulatory filings). Without verified plant-level linkage, naming specific supplier companies risks misattribution.
Who supplies sterile injectable fill-finish capacity?
Corvert is administered as a sterile injectable, so the supply chain usually includes a dedicated sterile fill-finish vendor with capabilities for:
- Sterile filtration and aseptic filling into vials
- Cold-chain compatible packaging
- Visual inspection and container closure integrity testing
- Regulatory-grade environmental monitoring and batch documentation
In practice, fill-finish suppliers for sterile injectables are often either:
- The commercial manufacturing site of record (if the brand owner owns the line), or
- A CDMO that performs aseptic fill-finish under contract
As with API suppliers, a correct “Corvert” supplier list requires verification of the specific fill-finish site used for the marketed product.
What suppliers provide the critical excipients and drug product components?
For ibutilide sterile injectable products, the drug product bill of materials typically includes:
- Buffer system components (pH control salts)
- Tonicity agents (commonly sodium-based)
- Stabilizers/chelators (where applicable)
- Bulking agents (if lyophilized, though injectable presentations are commonly ready-to-use for sterile formulations)
- Sterile water for injection grade
- Container closure system components:
- Injection vials
- Rubber stoppers
- Aluminum seals
- Labels and cartons
These categories map to specialized supplier networks:
- Excipients: global commodity- and pharma-grade excipient producers (API-grade and USP/NF grade availability)
- Sterile components: container closure system manufacturers with compatibility and extractables/leachables documentation
What about device and packaging suppliers?
Corvert-type sterile injectable supply typically uses standardized packaging with tight traceability:
- Vial manufacturing and inspection suppliers
- Stopper extrusion and coating suppliers
- Seal and label production suppliers
- Serialization-ready packaging lines (where required)
Brand packaging supplier mapping depends on the pack configuration used in each market and the regulatory dossier for the marketed strength and presentation.
How do you construct a defensible “suppliers for Corvert” list?
A defensible supplier list must tie each supplier to plant-level activity (API site, sterile fill-finish site, packaging site) and ideally to regulatory dossier references. That requires the product’s:
- Manufacturing sites of record for finished drug product
- API source plants and salt form
- Packaging and labeling sites
Key Takeaways
- “Suppliers for Corvert” requires plant-level mapping from regulatory filings to avoid misidentifying API and fill-finish vendors.
- For Corvert-like sterile injectable products, the supplier set concentrates in four upstream segments: ibutilide API, aseptic fill-finish, excipients and sterile bulk, and container closure and packaging.
- A correct list of named companies depends on verified manufacturing site of record and API sourcing sites tied to the marketed presentations.
FAQs
-
Is Corvert an oral or injectable drug?
Corvert is a sterile injectable product (ibutilide-based).
-
What upstream supplier types matter most for continuity?
Ibutilide API suppliers and sterile fill-finish/CDMO sites are usually the highest-impact constraints.
-
Do packaging suppliers affect regulatory compliance?
Yes, container closure systems and packaging components must match documented specs and compatibility data.
-
Can the same supplier make both API and finished sterile drug product?
It is possible but not guaranteed; many brands use separate API manufacturers and sterile fill-finish CDMOs.
-
What data element is required to name specific Corvert suppliers?
The product’s disclosed manufacturing site(s) of record and API supplier sites from regulatory filings.
References (APA)
[1] FDA. (n.d.). Drugs@FDA: Drug product and labeling information (for ibutilide-containing products and associated manufacturing information). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
